Prevalence and Outcome of SARS-CoV-2 Infection & COVID-19 in Transplant Recipients: The COVITRA Study

Universitaire Ziekenhuizen KU Leuven

Status: Enrolling

Conditions: SARS-CoV Infection; Transplantation Infection; Covid19

Treatments: Diagnostic Test: SARS-CoV-2 IgG

Study type: Observational

Funder types: Other

Identifiers

NCT04579471

s64036

Details and patient eligibility

About

This project will provide novel data using a large cohort of more than 3000 transplanted patients. Risk and protective factors for SARS-CoV-2 infection and COVID-19 disease severity will be identified. The proportion of patients who develop antibodies after infection will be revealed. In this way the presence of these antibodies can be evaluated as a test for prior infection. Our study additionally will demonstrate how long these antibodies remain present and whether they are protective against a new infection.

Enrollment: 2,000 estimated patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• all patients who underwent solid organ or hematopoietic cell transplantation at UZ Leuven and who give informed consent

Exclusion criteria

• age under 18 years

Trial design

2,000 participants in 3 patient groups

Transplanted patients

Description:

All patients who underwent solid organ or hematopoietic cell transplantation at UZ Leuven

Treatment:

Diagnostic Test: SARS-CoV-2 IgG

Transplanted patients with past SARS-CoV-2 infection

Description:

Transplanted patients with past SARS-CoV-2 infection will be followed for one year (at month 3, 6 and 12 after the initial study visit) to assess durability of IgG positivity

Treatment:

Diagnostic Test: SARS-CoV-2 IgG

Transplanted patients without past SARS-CoV-2 infection

Description:

100 transplanted patients without past SARS-CoV-2 infection will be followed for one year (at month 3, 6 and 12 after the initial study visit) to assess durability of IgG positivity and as control for the transplanted patients with WITH past SARS-CoV-2 infection

Treatment:

Diagnostic Test: SARS-CoV-2 IgG